Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

EXAGEN INC. (XGN)

As of 2026-11-17 · 13/15 boxes filled from SEC filings and market data

Report price $3.77 (close 2026-11-16); latest close $3.61 (2026-11-20), -4.2% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -28% · upside +20%

At today’s price the market pays EV/Sales of 1.29x and P/S of 1.33x, essentially the company’s own 1.3x five-year median, for a business with EBIT of -$14.5M, EBITDA of -$12.0M, net income of -$18.2M and free cash flow of -$13.0M TTM; ROIC is -79.4% against a 14.8% WACC. The call is PASS because the quality gate fails—no moat is evidenced, ROIC is below WACC and the FCF yield is -13.5%—and because no independent multiple supports a base case. There is no base case: no comparable peer multiple sets one, and a base at the company’s own multiple today would be today’s price by construction. The downside is -31.1% to $2.60, on -20.0% sales at a compressed EV/Sales of 1.1x (today 1.29x). The upside is +14.6% to $4.32, on +15% sales at today’s EV/Sales of 1.29x. The label therefore rests on those two cases alone.

Key numbers

  • Share price: $3.61
  • Market cap: $92.1M
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $72.3M
  • FCF yield: -14.1%
  • Price / book: 6.68x
  • Earnings-quality flags (TTM): Mark-to-market on the company's own stock (warrants) $1.1M (6% of net income)
  • Revenue growth (latest fiscal year): +19.7%
  • ROIC (TTM): -79.4%
  • WACC: 14.8%
  • Economic profit spread: -94.3 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Exagen is a rheumatology-focused testing company whose revenue comes mainly from reimbursement for AVISE CTD, which was 91% of revenue in FY2025 and FY2024. FY2025 revenue was a record $66.6M, up 19.7% from FY2024, and XBRL shows revenue at $72.3M TTM to 2026-09-30, but operating income, net income and operating cash flow remain negative. The business changed from the FY2020 10-K's integrated testing-and-therapeutics model and ~5,000-rheumatologist target to a FY2025 testing-focused operational turnaround targeting ~6,000 rheumatologists, with losses still persistent.

  2. ✓ 2. Competitive advantage

    No durable moat is visible. The 10-K names the traditional ANA/anti-dsDNA/C3/C4 workup and the existing infrastructures of ARUP, LabCorp, Mayo Clinic and Quest as the competition, and admits it has no contracts with significant private payors. Revenue grew from $42.0M in FY2020 to $72.3M in the TTM to 2026-09-30, yet operating income was negative in all seven periods on file and was still -$14.5M in the TTM, so growth has not turned into pricing power or operating leverage.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 revenue was $18.4 million, up 6.8% (7% in the release) on AVISE CTD test volume up ~2% and trailing-twelve-month ASP up $10 to $451, with gross margin 58.8% versus 58.4%. Growth is not yet dropping to operating profit: operating loss widened to $(4.4) million in Q3 2026 from $(3.1) million as SG&A rose 12.1% and a $587,000 IPR&D charge landed, while the smaller net loss ($(6.3) million versus $(7.1) million) was helped by a smaller warrant revaluation. Cash fell to $28.1 million at September 30, 2026 from $35.7 million a year earlier, partly offset by $6.7 million gross of ATM stock sold in the quarter; FY2026 revenue guidance is still $72-75 million.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ✓ 11. Impression of the shareholder letter

    Filled; members read this box.

  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans